Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Am J Hypertens. 2021 Jun 22;34(6):569-577. doi: 10.1093/ajh/hpab021.
Hypertension is a highly prevalent and causal risk factor for cardiovascular disease (CVD). Quantitative cardiovascular (CV) risk assessment is a new paradigm for stratifying hypertensive patients into actionable groups for clinical management and prevention of CVD. The large heterogeneity in hypertensive patients makes this evaluation complex, but recent advances have made CV risk assessment more feasible. In this review, we first describe the prognostic significance of various levels and temporal patterns of blood pressure (BP). We then discuss CV risk prediction equations and the rationale of taking global risk into account in hypertensive patients. Finally, we review several adjunctive biomarkers that may refine risk assessment in certain patients. We observe that, beyond individual cross-sectional measurements, both short-term and long-term BP patterns are associated with incident CVD; that current CV risk prediction performs well, and its incorporation into hypertension management is associated with potential population benefit; and that adjunctive biomarkers of target organ damage show the most promise in sequential screening strategies that target biomarker measurement to patients in whom the results are most likely to change clinical management. Implementation of quantitative risk assessment for CVD has been facilitated by tools and direct electronic health record integrations that make risk estimates accessible for counseling and shared decision making for CVD prevention. However, it should be noted that treatment does not return an individual to the risk of someone who never develops hypertension, underscoring the need for primordial prevention in addition to continued innovation in risk assessment.
高血压是一种普遍存在且可导致心血管疾病(CVD)的风险因素。定量心血管(CV)风险评估是一种将高血压患者分层为可采取行动的临床管理和 CVD 预防组的新方法。高血压患者的异质性很大,使得这种评估变得复杂,但最近的进展使 CV 风险评估变得更加可行。在这篇综述中,我们首先描述了各种血压(BP)水平和时间模式的预后意义。然后,我们讨论了 CV 风险预测方程以及在高血压患者中考虑整体风险的原理。最后,我们回顾了一些可能在某些患者中改善风险评估的辅助生物标志物。我们观察到,除了个体的横断面测量外,短期和长期 BP 模式都与 CVD 事件有关;目前的 CV 风险预测表现良好,将其纳入高血压管理与潜在的人群获益相关;并且,靶器官损伤的辅助生物标志物在针对最有可能改变临床管理的患者进行生物标志物测量的连续筛查策略中显示出最大的前景。用于 CVD 的定量风险评估的实施得益于工具和直接的电子健康记录集成,这些工具和集成使风险估计可用于咨询和 CVD 预防的共享决策。然而,应该注意的是,治疗并不能使个体恢复到从未发生高血压的人的风险水平,这突出了除了继续创新风险评估外,还需要进行原始预防。